CTLA4 and hepatocellular carcinoma: Combination therapy with the anti-PD-L1 antibody durvalumab with anti-CTLA-4 antibody tremelimumab for unresectable HCC cases has surpassed the control drug sorafenib in the HIMALAYA trial and has been approved as a first-line therapy [15].